Consider LINZESS for appropriate adult patients

According to a survey, patients with symptoms associated with Irritable Bowel Syndrome with Constipation (IBS-C) or Chronic Idiopathic Constipation (CIC) tend to self-manage their condition with over-the-counter (OTC) medications, cycling through 4-5 products on average. Patients were triggered to leave the “self-care cycle” and seek medical care when OTC and diet/lifestyle changes did not improve symptoms3

  • Patients frustrated by persistent symptoms3
  • Patients dissatisfied with OTC remedies3
  • Patients who have failed multiple OTC options3
  • Patients seeking effective FDA-approved treatment1

Talking to patients about their symptoms

Getting sufferers to talk about their condition can be a challenge. Many patients with IBS-C or CIC find their condition embarrassing to talk about and may not think to bring up multiple symptoms.14 Because IBS‑C and CIC are multi‑symptom conditions, additional prompting may be required for patient assessment.15

Start the conversation

To help you break down the barriers to communication and foster an open dialogue, view our Constipation Conversation Tool.

Keep your ears open

Patients may describe their symptoms in many different ways. Here are a few terms that are important to listen for1:

IBS-C symptoms

Belly pain

Constipation

Infrequent and incomplete bowel movements

CIC symptoms

Constipation

Hard stools

Infrequent and incomplete bowel movements

Listen for clues

IBS-C and CIC are chronic conditions, which can cause your patients to suffer on a recurrent basis. While there is no cure for IBS‑C or CIC, patients often try to manage their symptoms by5,15-20:

  • Making dietary changes
  • Drinking more water
  • Increasing exercise
  • Taking OTC laxatives and stool softeners, some of which are only intended for up to 7 days of use
  • Reducing stress

Hear what patients have to say about IBS-C and CIC in their own words

Watch patients discuss how their condition really makes them feel and how LINZESS helped.

Watch videos

Despite their effort, recurring symptoms leave many patients with IBS-C or CIC frustrated with traditional therapies.3,15

Patients who are suffering from IBS-C or CIC would likely welcome an option that can help them proactively manage their symptoms.1

Effective treatment is important for your IBS-C and CIC patients

Based on a survey commissioned by Ironwood and Forest, over half of IBS-C sufferers,
and more than 40% of CIC sufferers, sought medical care, but often did not receive a prescription.3

LINZESS is a once-daily treatment that allows patients with IBS-C and CIC to proactively manage their symptoms1

Know what to look for

One of the best ways to identify appropriate patients who can benefit from proactive treatment with LINZESS1 is to review examples of common patient profiles. The sample patients detailed below were based on patient characteristics, including varying symptom severity, of pivotal LINZESS trials.1

Select a patient profile below to learn about their journey with IBS-C or CIC.

IBS-C

CIC

*Not actual patients. For illustration purposes only.

Next: Disease Information

Important Safety Information

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

LINZESS is contraindicated in patients less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. Use of LINZESS should be avoided in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS has not been established in patients less than 18 years of age.

Contraindications
  • LINZESS is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pediatric Risk
  • LINZESS is contraindicated in patients less than 6 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established. In neonatal mice, linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.
  • Use of LINZESS should be avoided in pediatric patients 6 to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age.
Diarrhea
  • Diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.
Common Adverse Reactions (incidence ≥2% and greater than placebo)
  • In IBS-C clinical trials: diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
  • In CIC trials of a 145 mcg dose: diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%). In a CIC clinical trial of a 72 mcg dose: diarrhea (19% vs 7% placebo) and abdominal distention (2% vs <1%).

LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC).

If you are a patient, and have any questions, please discuss them with your doctor or healthcare professional. For additional information about LINZESS, call Allergan Customer Relations and Medical Affairs at 1-800-678-1605.

Please see below and full Prescribing Information for LINZESS.

Show
Important Safety Information

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

LINZESS is contraindicated in patients less than 6 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration. Use of LINZESS should be avoided in patients 6 years to less than 18 years of age. The safety and effectiveness of LINZESS has not been established in patients less than 18 years of age.

Contraindications
  • LINZESS is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Pediatric Risk
  • LINZESS is contraindicated in patients less than 6 years of age. The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established. In neonatal mice, linaclotide increased fluid secretion as a consequence of GC-C agonism resulting in mortality within the first 24 hours due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe diarrhea and its potentially serious consequences.
  • Use of LINZESS should be avoided in pediatric patients 6 to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, use of LINZESS should be avoided in pediatric patients 6 years to less than 18 years of age.
Diarrhea
  • Diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.
Common Adverse Reactions (incidence ≥2% and greater than placebo)
  • In IBS-C clinical trials: diarrhea (20% vs 3% placebo), abdominal pain (7% vs 5%), flatulence (4% vs 2%), headache (4% vs 3%), viral gastroenteritis (3% vs 1%) and abdominal distension (2% vs 1%).
  • In CIC trials of a 145 mcg dose: diarrhea (16% vs 5% placebo), abdominal pain (7% vs 6%), flatulence (6% vs 5%), upper respiratory tract infection (5% vs 4%), sinusitis (3% vs 2%) and abdominal distension (3% vs 2%). In a CIC clinical trial of a 72 mcg dose: diarrhea (19% vs 7% placebo) and abdominal distention (2% vs <1%).

LINZESS® (linaclotide) is indicated in adults for the treatment of both irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC).

If you are a patient, and have any questions, please discuss them with your doctor or healthcare professional. For additional information about LINZESS, call Allergan Customer Relations and Medical Affairs at 1-800-678-1605.

Please see below and full Prescribing Information for LINZESS.